The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 28, 2020
Filed:
May. 24, 2016
Applicant:
Sabre Therapeutics Llc, South San Francisco, CA (US);
Inventors:
Gretchen Bain, San Diego, CA (US);
Jillian Frances Evans, San Diego, CA (US);
John Howard Hutchinson, San Diego, CA (US);
David Lonergan, San Marcos, CA (US);
Assignee:
SABRE THERAPEUTICS LLC, South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/44 (2006.01); A61K 31/4155 (2006.01); A61P 7/06 (2006.01); A61P 19/04 (2006.01); A61P 27/02 (2006.01); A61P 17/06 (2006.01); A61P 21/04 (2006.01); A61P 9/10 (2006.01); A61P 25/28 (2006.01); A61P 1/16 (2006.01); A61P 11/06 (2006.01); A61P 3/04 (2006.01); A61P 15/02 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 9/12 (2006.01); A61P 13/10 (2006.01); A61P 1/00 (2006.01); A61P 5/00 (2006.01); A61P 11/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 17/04 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/4439 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4155 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/4439 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 5/00 (2018.01); A61P 7/06 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 11/06 (2018.01); A61P 13/10 (2018.01); A61P 15/02 (2018.01); A61P 17/00 (2018.01); A61P 17/04 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 19/04 (2018.01); A61P 21/04 (2018.01); A61P 25/00 (2018.01); A61P 25/28 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01);
Abstract
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.